If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-21. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
The human brain contains multiple regions, as does the spinal cord. There are multiple ways to divide the brain, including by the embryological development of the brain; into three parts: the cerebellum, brainstem, and cerebrum; the evolution of the brain; and cytoarchitecture, as in the case of Brodmann areas. A popular model of the 'triune brain' — comprising the reptilian complex (basal ganglia), the paleomammalian complex (limbic system), and the neomammalian complex (neocortex) — was formerly popular during the 1960s, though is now regarded as a myth. 'Limbic system' and associated terms, however, remain in neuroanatomical use, although some neuroscientists have argued against such use.
== See also == Substituted methylenedioxyphenethylamine I Feel Love: MDMA and the Quest for Connection in a Fractured World Lykos Therapeutics Multidisciplinary Association for Psychedelic Studies (MAPS) Non-racemic MDMA and (R)-MDMA Carina Leveriza-Franz
== History == Initially released in 2002, the VADAR web server has gone through a number of revisions and updates (now in version 1.8). The latest version of the VADAR web server supports the submission of either PDB formatted files or PDB accession numbers and generates extensive tables and high quality graphs for quantitatively and qualitatively assessing protein structures determined by X-ray crystallography, NMR spectroscopy, 3D-threading or homology modelling. A separate website supports the analysis of multiple protein chains – as might be generated from a standard NMR structure determination effort.
Afferent nerves conduct sensory information from sensory neurons to the central nervous system, for example from the mechanoreceptors in skin. Bundles of afferent fibers are known as sensory nerves. Efferent nerves conduct signals from the central nervous system along motor neurons to their target muscles and glands. Bundles of these fibres are known as efferent nerves. Mixed nerves contain both afferent and efferent axons, and thus conduct both incoming sensory information and outgoing muscle commands in the same bundle. All spinal nerves are mixed nerves, and some of the cranial nerves are also mixed nerves. Nerves can be categorized into two groups based on where they connect to the central nervous system:
Sources: en.wikipedia.org
The trade is now considered one of the most one-sided trades in baseball history; in 2001, ESPN's readers named it the second-worst trade in sports history, behind only the Red Sox trading Ruth to the New York Yankees. Although Andersen pitched well down the stretch in 1990, he allowed three runs in 22 innings to help the Red Sox secure the American League East division title on the final day of the season, the Oakland Athletics swept them out of the American League Championship Series (ALCS). They then lost Andersen after the season when he was declared a "new-look" free agent due to the third collusion settlement. According to the Red Sox' then-general manager, Lou Gorman, the trade made sense at the time. Gorman spent the ensuing years defending the decision-making process that led up to the Bagwell trade. In his 2005 autobiography, One Pitch from Glory, Gorman noted that Boston already had Wade Boggs at the major league level at third base, and had rated prospects Tim Naehring and Scott Cooper higher than Bagwell on the organization's depth chart. Bagwell had seen some time in the minors at first base, but he was blocked from that position by Mo Vaughn. Gorman pursued Andersen only after receiving assurances from MLB's player relations committee that Andersen would not be lost to the new-look free agency. Nevertheless, it is considered one of the most one-sided trades in baseball history. Not only did the Red Sox lose Andersen to free agency after one month, but both Naehring and Cooper were out of baseball by 1997.
Some nuclear submarines such as the American Ohio class can operate with their reactor coolant pumps secured, making them quieter than electric subs. A conventional submarine operating on batteries is almost completely silent, the only noise coming from the shaft bearings, propeller, and flow noise around the hull, all of which stops when the sub hovers in mid-water to listen, leaving only the noise from crew activity. Commercial submarines usually rely only on batteries, since they operate in conjunction with a mother ship. Several serious nuclear and radiation accidents have involved nuclear submarine mishaps. The Soviet submarine K-19 reactor accident in 1961 resulted in 8 deaths and more than 30 other people were over-exposed to radiation. The Soviet submarine K-27 reactor accident in 1968 resulted in 9 fatalities and 83 other injuries. The Soviet submarine K-431 accident in 1985 resulted in 10 fatalities and 49 other radiation injuries.
Thirty radioisotopes of protactinium have been discovered, ranging from 210Pa to 239Pa. The most stable are 231Pa with a half-life of 32,650 years, 233Pa with a half-life of 26.975 days, and 230Pa with a half-life of 17.4 days. All other isotopes have half-lives shorter than 1.6 days, and the majority of these have half-lives less than 1.8 seconds. Protactinium also has six nuclear isomers, with the most stable being 234mPa (half-life 1.159 minutes). The primary decay mode for the most stable isotope 231Pa and lighter isotopes (210Pa to 227Pa) is alpha decay, producing isotopes of actinium. The primary decay mode for 228Pa to 230Pa is electron capture or beta plus decay, producing isotopes of thorium, while the primary decay mode for the heavier isotopes (232Pa to 239Pa) is beta decay, producing isotopes of uranium.
Lactoferrin (LF), also known as lactotransferrin (LTF), is a multifunctional protein found in milk and mucus which is encoded by the LTF gene in humans. Lactoferrin functions as an antimicrobial protein, and also impacts the body's immune response in a complex way, with both pro- and anti-inflammatory effects. This protein is part of the transferrin family. Lactoferrin is a globular glycoprotein with a molecular mass of about 80 kDa that is widely represented in various secretory fluids, such as milk, saliva, tears, and nasal secretions. Lactoferrin is also present in secondary granules of PMNs and is secreted by some acinar cells. Lactoferrin can be purified from milk or produced recombinantly. Human colostrum ("first milk") has the highest concentration, followed by human milk, then cow milk (150 mg/L). Lactoferrin is one of the components of the immune system of the body; it has antimicrobial activity (bacteriocide, fungicide) and is part of the innate defense, mainly at mucosas. It is constantly produced and released into saliva, tears, as well as seminal and vaginal fluid. Lactoferrin provides antibacterial activity to human infants. Lactoferrin interacts with DNA and RNA, polysaccharides and heparin, and shows some of its biological functions in complexes with these ligands. Lactoferrin supplements reduce the risk of respiratory tract infections, based on a recent meta-analysis of randomized controlled trials.
In dependent smokers, withdrawal causes impairments in memory and attention, and smoking during withdrawal returns these cognitive abilities to pre-withdrawal levels. The temporarily increased cognitive levels of smokers after inhaling smoke are offset by periods of cognitive decline during nicotine withdrawal. Therefore, the overall daily cognitive levels of smokers and non-smokers are roughly similar. Nicotine activates the mesolimbic pathway and induces long-term ΔFosB expression (i.e., produces phosphorylated ΔFosB isoforms) in the nucleus accumbens when inhaled or injected frequently or at high doses, but not necessarily when ingested. Consequently, high daily exposure (possibly excluding oral route) to nicotine can cause ΔFosB overexpression in the nucleus accumbens, resulting in nicotine addiction.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.